A comprehensive view of neurological/cognitive health. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Japan’s Eisai Co. reports its injectable Alzheimer’s drug lecanemab, reduced clinical decline in patients with early-stage Alzheimer’s by 27% in late-stage study; Eisai seeks accelerated approval from FDA, with Eisai and Biogen co-promoting the drug
Published: September 28, 2022 by Associated Press
Teva launches Honestly HD website to provide information, resources for patients with Huntington’s Disease chorea, a movement disorder that causes involuntary body movements; website offers information about how to talk to healthcare providers
Published: September 26, 2022 by Business Wire
UBS upgrades Eli Lilly to buy from neutral, as company starts submitting marketing application for late-stage Alzheimer’s medication Donanemab, which could be 'biggest drug ever' and 'highest potential late-stage Alzheimer’s asset'
Published: September 22, 2022 by Finbold
Bluebird Bio breaks treatment pricing record after receiving FDA accelerated approval for gene therapy Skysona to treat cerebral adrenoleukodystrophy, a rare pediatric neurological disorder; Bluebird to charge US$3.0M per treatment with Skysona
Published: September 21, 2022 by FiercePharma
Scientists find bioactive compounds in beetroot, carrot juice have neuroprotective effect in rats exposed to cadmium
Published: September 13, 2022 by MDPI

Ask us about our Consumer Wellness market view

Trending Chart

Interactive chart with headline count